RPS6KB2 and neoplasm: Phosphoproteomic data also revealed trends of upregulation of phosphorylation at sites that activate two kinases (CDK7[T170], RPS6KB2(S6K2) [S423]) after treatment in the post-treatment tumor of Patient 4 compared with those of the other patients (Fig. S5, Table S7).